171 related articles for article (PubMed ID: 16761906)
1. Dalteparin versus warfarin for the prevention of recurrent venous thromboembolic events in cancer patients: a pharmacoeconomic analysis.
Dranitsaris G; Vincent M; Crowther M
Pharmacoeconomics; 2006; 24(6):593-607. PubMed ID: 16761906
[TBL] [Abstract][Full Text] [Related]
2. Economic Analysis Comparing Dalteparin to Vitamin K Antagonists to Prevent Recurrent Venous Thromboembolism in Patients With Cancer Having Renal Impairment.
Dranitsaris G; Shane L; Burgers L; Woodruff S
Clin Appl Thromb Hemost; 2016 Oct; 22(7):617-26. PubMed ID: 27436663
[TBL] [Abstract][Full Text] [Related]
3. Extended dalteparin prophylaxis for venous thromboembolic events: cost-utility analysis in patients undergoing major orthopedic surgery.
Dranitsaris G; Stumpo C; Smith R; Bartle W
Am J Cardiovasc Drugs; 2009; 9(1):45-58. PubMed ID: 19178131
[TBL] [Abstract][Full Text] [Related]
4. Dalteparin or vitamin K antagonists to prevent recurrent venous thromboembolism in cancer patients: a patient-level economic analysis for France and Austria.
Dranitsaris G; Shane LG; Galanaud JP; Stemer G; Debourdeau P; Woodruff S
Support Care Cancer; 2017 Jul; 25(7):2093-2102. PubMed ID: 28204995
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of dalteparin for preventing venous thromboembolism in abdominal surgery.
Heerey A; Suri S
Pharmacoeconomics; 2005; 23(9):927-44. PubMed ID: 16153135
[TBL] [Abstract][Full Text] [Related]
6. Dalteparin versus vitamin K antagonists for the prevention of recurrent venous thromboembolism in patients with cancer and renal impairment: a Canadian pharmacoeconomic analysis.
Dranitsaris G; Shane LG; Crowther M; Feugere G; Woodruff S
Clinicoecon Outcomes Res; 2017; 9():65-73. PubMed ID: 28138260
[TBL] [Abstract][Full Text] [Related]
7. Selecting an anticoagulant for recurrent venous thromboembolism in cancer.
Goodin S
Am J Health Syst Pharm; 2005 Nov; 62(22 Suppl 5):S10-3. PubMed ID: 16286363
[TBL] [Abstract][Full Text] [Related]
8. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Lee AY; Levine MN; Baker RI; Bowden C; Kakkar AK; Prins M; Rickles FR; Julian JA; Haley S; Kovacs MJ; Gent M;
N Engl J Med; 2003 Jul; 349(2):146-53. PubMed ID: 12853587
[TBL] [Abstract][Full Text] [Related]
9. Clinical and economic benefits of extended treatment with apixaban for the treatment and prevention of recurrent venous thromboembolism in Canada.
Quon P; Le HH; Raymond V; Mtibaa M; Moshyk A
J Med Econ; 2016 Jun; 19(6):557-67. PubMed ID: 26761644
[TBL] [Abstract][Full Text] [Related]
10. Low-molecular-weight heparin versus warfarin for secondary prophylaxis of venous thromboembolism: a cost-effectiveness analysis.
Marchetti M; Pistorio A; Barone M; Serafini S; Barosi G
Am J Med; 2001 Aug; 111(2):130-9. PubMed ID: 11498067
[TBL] [Abstract][Full Text] [Related]
11. Cancer-associated thrombosis: focus on extended therapy with dalteparin.
Bick RL
J Support Oncol; 2006 Mar; 4(3):115-20. PubMed ID: 16553136
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients.
Fowler RA; Mittmann N; Geerts W; Heels-Ansdell D; Gould MK; Guyatt G; Krahn M; Finfer S; Pinto R; Chan B; Ormanidhi O; Arabi Y; Qushmaq I; Rocha MG; Dodek P; McIntyre L; Hall R; Ferguson ND; Mehta S; Marshall JC; Doig CJ; Muscedere J; Jacka MJ; Klinger JR; Vlahakis N; Orford N; Seppelt I; Skrobik YK; Sud S; Cade JF; Cooper J; Cook D; ;
JAMA; 2014 Nov; 312(20):2135-45. PubMed ID: 25362228
[TBL] [Abstract][Full Text] [Related]
13. [Economic analysis of dalteparin use in knee surgery at Instituto Mexicano del Seguro Social].
Arreola-Ornelas H; Rosado-Buzzo A; García-Mollinedo L; Dorantes Aguilar J; Muciño-Ortega E; Mould-Quevedo JF
Cir Cir; 2012; 80(5):411-8. PubMed ID: 23351443
[TBL] [Abstract][Full Text] [Related]
14. Economic Evaluation of the Combined Use of Warfarin and Low-dose Aspirin Versus Warfarin Alone in Mechanical Valve Prostheses.
El-Hamamsy MH; Elsisi GH; Eldessouki R; Elmazar MM; Taha AS; Awad BF; Elmansy H
Appl Health Econ Health Policy; 2016 Aug; 14(4):431-440. PubMed ID: 27028445
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of rivaroxaban versus warfarin anticoagulation for the prevention of recurrent venous thromboembolism: a U.S. perspective.
Seaman CD; Smith KJ; Ragni MV
Thromb Res; 2013; 132(6):647-51. PubMed ID: 24139508
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of low-molecular-weight heparin for secondary prophylaxis of cancer-related venous thromboembolism.
Aujesky D; Smith KJ; Cornuz J; Roberts MS
Thromb Haemost; 2005 Mar; 93(3):592-9. PubMed ID: 15735815
[TBL] [Abstract][Full Text] [Related]
17. The cost-effectiveness of extended-duration antithrombotic prophylaxis after total hip arthroplasty.
Skedgel C; Goeree R; Pleasance S; Thompson K; O'brien B; Anderson D
J Bone Joint Surg Am; 2007 Apr; 89(4):819-28. PubMed ID: 17403806
[TBL] [Abstract][Full Text] [Related]
18. Low-molecular-weight heparins for the prevention of recurrent venous thromboembolism in patients with cancer: A systematic literature review of efficacy and cost-effectiveness.
Dranitsaris G; Shane LG; Woodruff S
J Oncol Pharm Pract; 2019 Jan; 25(1):68-75. PubMed ID: 28857713
[TBL] [Abstract][Full Text] [Related]
19. Management of venous thromboembolism in patients with cancer: role of dalteparin.
Linkins LA
Vasc Health Risk Manag; 2008; 4(2):279-87. PubMed ID: 18561503
[TBL] [Abstract][Full Text] [Related]
20. Dalteparin compared with an oral anticoagulant for thromboprophylaxis in patients with cancer.
Kaufman JL
N Engl J Med; 2003 Oct; 349(14):1385-7; author reply 1385-7. PubMed ID: 14526769
[No Abstract] [Full Text] [Related]
[Next] [New Search]
